Your session is about to expire
← Back to Search
Other
Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
Phase 2
Waitlist Available
Led By Rajat Dhar, MD
Research Sponsored by Prolong Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 days
Awards & highlights
No Placebo-Only Group
Summary
Safety and effect of SANGUINATE on patients DCI following SAH.
Eligible Conditions
- Cerebral Ischemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 30 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Impact of SANGUINATE on brain oxygenation and blood flow assessed using Postitron Emission Tomography (PET)
Safety of study drug during and following infusion as measured by vital signs, clinical signs, bioanalytical measures, or investigational drug-related adverse events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: SANGUINATE™Experimental Treatment1 Intervention
Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SANGUINATE™
2014
Completed Phase 2
~140
Find a Location
Who is running the clinical trial?
Prolong PharmaceuticalsLead Sponsor
14 Previous Clinical Trials
301 Total Patients Enrolled
Rajat Dhar, MDPrincipal InvestigatorBarnes Jewish Hospital/Washington University
2 Previous Clinical Trials
1,037 Total Patients Enrolled
Michael N Dirringer, MDStudy ChairBarnes Jewish Hospital/Washington University